Furthermore, recent clinical trials with crizanlizumab, a humanized P-selectin monoclonal antibody, have shown incredible promise, with patients with SCD who were treated with the drug, experiencing significantly fewer vaso-occlusive pain crises compared to patients on placebo, although these studies have no cerebral endpoints (38, 87). Here, SELP is linked to Schnyder corneal dystrophy.